跳转至内容
Merck
CN

SML2163

HPN-07

≥98% (HPLC), sulfatase 2 (SULF2) inhibitor , powder

别名:

2, 4-Disulfonyl PBN, 2,4-Disulfophenyl-N-tert-butylnitrone, ARL 16556, CPI 22, Cerovive, Disodium 4-[(tert-butyl-imino) methyl]benzene-13-disulfonate N-oxide, Disufenton sodium, NXY-059, Nxy 059, OKN-007, OKN007, Oklahoma nitrone-007

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C11H13NO7S2 · 2Na
化学文摘社编号:
分子量:
381.33
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

HPN-07, ≥98% (HPLC)

InChI

1S/C11H15NO7S2.2Na/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19;;/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19);;/q;2*+1/p-2

SMILES string

[O-]/[N+](C(C)(C)C)=C\C(C=CC(S([O-])(=O)=O)=C1)=C1S([O-])(=O)=O.[Na+].[Na+]

InChI key

XLZOVRYBVCMCGL-UHFFFAOYSA-L

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

−20°C

Biochem/physiol Actions

Orally available NO-mimicking free radical trapping agent and sulfatase 2 (SULF2) inhibitor with in vivo efficacy in animal models of glioma and stroke.
Originally characterized for its NO-mimicking activity in preventing peroxynitrite formation and in vivo neuroprotective efficacy in animal models of cerebral ischemia (100 mg/kg i.v. in rabbits; 30-60 mg/kg plus 30-60 mg/kg/h i.v. or 50 mg/kg plus 8.8 mg/kg/h s.c. in rats; 28 mg/kg plus 16 mg/kg/h i.v. in monkeys), OKN-007 (HPN-07, NXY-059) is an orally available α-phenyl-tert-butylnitrone (PBN) derivative that is also shown to exhibit sulfatase 2 (SULF2) inhibitory activity and anticancer efficacy both in cultures (effective conc. 170-200 μM in Huh7 heptoma cultures) and in several rodent glioma models in vivo (C6, RG2, and GL261; 75 mg/kg/day for rats and 168 mg/kg/day for mice via drinking water).

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Paul A Lapchak et al.
Stroke, 33(6), 1665-1670 (2002-06-08)
It has been proposed that the novel spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059) may be useful in the treatment of ischemia and stroke. To date, there is little information concerning the safety of NXY-059 when administered in combination with the
Ting He et al.
Free radical biology & medicine, 51(2), 490-502 (2011-05-24)
Gliomas, the most common primary brain tumors in adults, have a poor outcome. PBN (α-phenyl-tert-butylnitrone) and OKN007 (2,4-disulfophenyl-PBN) are nitrones that have demonstrated beneficial effects in many aging diseases. In this study, we evaluated the anti-tumor effects of PBN and
J W Marshall et al.
Stroke, 32(1), 190-198 (2001-01-04)
NXY-059 is a novel nitrone with free radical-trapping properties that has a considerable neuroprotective effect in rats. We have now examined the efficacy of this drug at reducing long-term functional disability in a primate model of stroke. Twelve monkeys were
Philippe Garteiser et al.
Journal of magnetic resonance imaging : JMRI, 31(4), 796-806 (2010-04-08)
To demonstrate that OKN007, a disulfonyl derivative of phenyl-tert-butyl nitrone (PBN), has anti-glioma activity in the clinically relevant C6 rat glioma model using multi-parametric magnetic resonance imaging. Twenty-one rats were intracerebrally implanted with C6 cells and administered OKN007 or kept
Z Zhao et al.
Brain research, 909(1-2), 46-50 (2001-08-02)
Free radicals have gained wide acceptance as mediators of cerebral ischemic injury. It has previously been reported that a spin trap nitrone, alpha-phenyl-N-tert-butyl nitrone (PBN), can reduce infarct volumes in rats subjected to either permanent or transient focal cerebral ischemia.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持